Combination of Misoprostol and Oxytocin for Effective Control of Postpartum Hemorrhage During Cesarean Section

Objective: This study is to analyze the value of combining misoprostol and oxytocin in the prevention and control of postpartum hemorrhage during cesarean section. Methods: 82 cesarean section patients from July 2023 to July 2024 were selected as samples and randomly divided into two groups. Group A received misoprostol combined with oxytocin treatment, while Group B received only misoprostol treatment. The amount of postpartum hemorrhage, coagulation indicators, postpartum recovery indicators, and adverse reactions were compared between the two groups. Results: The intraoperative, 2-hour postpartum, 2-24-hour postpartum, and total blood loss in Group A were all lower than those in Group B (P < 0.05). The activated partial thromboplastin time (APTT), plasma prothrombin time (PT), fibrinogen (FIB), and thrombin time (TT) in Group A were all lower than those in Group B (P < 0.05). The first exhaust time, first time out of bed, and hospital stay after cesarean section in Group A were all shorter than those in Group B (P < 0.05). The adverse reaction rate in Group A was lower than that in Group B (P < 0.05). Conclusion: The application of misoprostol combined with oxytocin during cesarean section can optimize coagulation indicators, reduce blood loss, shorten postpartum recovery time, and is highly effective and feasible.